A new report looking at the booming market for immuno-oncology treatments has quantified the rise in clinical trials using PD-1 and PD-L1 antibodies, combined with other therapeutic approaches.
These therapies seek to interrupt a biochemical shield created when a tumor combines a protein called programmed death ligand-1 (PD-L1) with another found in the body’s immune system, called programmed death-1 (PD-1).
The report from EP Vantage finds that, as of April 2017, there were 765 studies of this type, an increase from the 215 found in November 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze